World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 


A miracle treatment for TB is a near possibility

New Drug Regimen: A miracle treatment for TB is a near possibility

Shobha Shukla, Citizen News Service (CNS)

Two years after launching a first of its kind Combination Drug Study for TB treatment in 2010, the Global Alliance for TB Drug Development (TB Alliance) raised hopes of a novel drug regimen to treat both forms of TB—drug sensitive (DS) and multi drug resistant (MDR) TB, at the XX International AIDS Conference (AIDS 2014) in Melbourne, offering a new paradigm in TB treatment to treat patients with drugs to which they are sensitive, rather than based on what they are resistant to.

Announcing the results of the PaMZ Phase 2b trial results, Dr Dan Everitt, Senior Medical Officer of TB Alliance, informed that the new combination drug regimen PaMZ is designed to treat both DS-TB and some forms of MDR-TB (which are not resistant to Moxifloxacin and Pyrazinamide) in a much shorter time.

PaMZ consists of two new drug candidates, PA-824 (Pa) and moxifloxacin (M) and pyrazinamide (Z) which is part of the current first-line treatment.

In an interview given to Citizen News Service (CNS), Dr Everitt said that, “We are extremely encouraged by the results of this trial. They were consistent with our predictions from earlier research and add strong evidence to support our belief that we are well on the way to substantially improved treatment for TB and many MDR-TB patients.”

The new regimen raises new hopes of having a much shorter, simpler, cheaper and effective treatment for DS-TB and MDR-TB. In case of MDR-TB, it not only promises to reduce treatment time to 6 months from the current 24 months, but also reduces 97% of the pill burden (from the existing over 14000 pills to 360 pills) and eliminates totally the need of injections. At the same time it also avoids interactions with antiretroviral drugs, improving treatment for the millions of HIV-TB co-infected patients.

Dr Everitt elaborated that this open-label randomized clinical trial to study the bactericidal activity of 8-weeks treatment with PaMZ in DS-TB and MDR-TB, was performed at 7 sites (5 in South Africa and 2 in Tanzania) on 181 DS-TB and 26 MDR-TB subjects, of whom 35% were female, and 20% were HIV-infected. However only 9 MDR-TB subjects could be included in the statistical analysis of the 8 weeks data, as others were late exclusions, as they were found resistant to pyrazinamide, and therefore ineligible for the trial.

The PaMZ regimen showed active bactericidal activity against both DS-TB and MDR-TB that extended from 2 weeks through 2 months and which was significantly greater than that of the existing standard HRZE (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) therapy in patients with DS-TB. All 3 experimental treatment arms had greater average reductions in CFU (colony forming units) counts than HRZE over 8 weeks.

When evaluated with the most sensitive diagnostic methods available (liquid culture), nearly twice as many TB patients treated with PaMZ (71%) produced TB-negative sputum cultures at the end of 2 month course of the trial, compared to patients treated with standard HRZE therapy (38%).

Thus PaMZ killed more bacteria than standard therapy and did so at a faster rate for both DS-TB and MDR-TB. It also showed compatibility with commons anti retro viral drugs (ARVs) as there appeared to be no interference or side effects between the PaMZ regimen and the common ARVs being taken by the TB-HIV co-infected patients. A formal statistical evaluation found no effect of HIV status on the outcome of the study. Also side effect profiles were encouraging and appeared consistent between both TB and MDR-TB patients.

TB Alliance, with the help of its global partners, now plans to advance PaMZ to a first ever global phase 3 clinical study named STAND (Shortening Treatments by Advancing Novel Drugs) by the end of 2014, testing a drug regimen for use against both DS-TB and MDR-TB, provided adequate funding is secured. STAND aims to enroll more than 1500 patients in more than 50 sites in 15 countries (spanning South Africa, Kenya, Tanzania, Uganda, Zambia, Malaysia, Thailand, China, Philippines, Peru, Brazil, Georgia, Ukraine, Russia, and Haiti), which will include a significantly larger number of MDR-TB patients.

If PaMZ performs successfully in the STAND trial, it will proceed to global registration and be made available to the people who need it.

STAND not only represents the hope of new TB cures, but also the promise of an innovative scientific approach to developing new products. If the STAND trial is successful, it will mark the first time a new TB drug regimen is developed and registered using a new model pioneered by TB Alliance that allows multiple new drugs to be developed at once –making a combination of drugs, and not a single drug, the basis for innovation.

Globally, every year 1.3 million people die from TB, while nearly 9 million more contract it. Also the disease is becoming increasingly resistant to the available drugs. Today, 650,000 patients around the world suffer from MDR-TB, and this number is expected to continue to rise. Most MDR-TB patients are unable to access adequate treatment due to the complexity and high cost of treatment. New regimens that are shorter, less costly, better tolerated, oral and compatible with anti-retroviral therapy are urgently needed to treat TB, especially MDR-TB.

Dr Mel Spigelman, President and CEO, TB Alliance told CNS that, “PaMZ continues to show game-changing potential for TB, and especially MDR-TB patients, as well as those co-infected with TB and HIV. We are working as quickly and diligently as possible to begin the next and final stage of PaMZ’s development, and continuing to seek financial support for STAND”.

ENDS

© Scoop Media

 
 
 
 
 
World Headlines

 

West Papua: “Lest We Forget”

AS Anzac approaches and Australians and New Zealanders remember those who fought and lost their lives on Anzac Day, it is hoped we will also remember the unfree people of the Pacific region and in particular those who are still suffering from human ... More>>

Iran: 81 Executions In One Week

Coincident with mass executions in the prisons of Ghezel-Hessar, Karaj and other cities, the anti-human regime of mullahs sent 16 other prisoners to the gallows in Mashhad and Birjand (northeastern Iran). Twelve of them were hanged collectively ... More>>

Al-Shabaab: Four Unicef Staff Killed In Somalia

Four UNICEF staff members have been killed in an attack on their vehicle in Garowe, Somalia. Four other UNICEF colleagues are in a serious condition. The IED (improvised explosive device) attack occurred when the staff were travelling from their guest ... More>>

UN: Suicide Attack In Jalalabad Condemned

NEW YORK/KABUL/GENEVA (18April 2015) – “I strongly condemn the brutal suicide attack that coincided with my visit to Jalalabad today,” said United Nations Assistant Secretary-General for Human Rights Ivan Šimonović during his visit to Afghanistan. ... More>>

Save The Children: STC Urges EU Leaders To Act To Prevent More Mass Drownings

Save the Children Urges EU Leaders to Act to Prevent More Mass Drownings at Sea. More>>

ALSO:

Japan: Independent Experts Slam Japan’s New Whaling Plan

Independent experts slam Japan’s new whaling plan and declare no more whales need to be killed for Antarctic research More>>

Gaza Strip: Attacks In The Border Areas

Following disengagement from the Gaza Strip in September 2005, Israel unilaterally and illegally established a so-called “buffer zone”, an area prohibited to Palestinians along the land and sea borders of the Gaza Strip. The precise area designated by ... More>>

Australian Government: Iraq Deployment: Joint Press Conference, Canberra

Back in March, the Government announced that we were preparing a force for a Building Partner Capacity training mission in Iraq. I can inform you that today the Cabinet has decided to deploy that force. The deployment will start tomorrow and we expect ... More>>

UNHRC: UN Committee Against Torture To Review New Zealand

UN Committee against torture to review New Zealand, Congo, Romania, Luxembourg, Spain, Serbia, Colombia, Former Yugoslav Republic of Macedonia More>>

UNHRC: Nigeria: One Year On, Call To Bring Back Abducted Children

Nigeria: One year on, UN and African experts call for decisive steps to bring back abducted children More>>

EU & US Let Iran Win Top Seat On UN Women’s Rights Board

EU & US Allowed Iran to Win Top Seat on UN Women’s Rights Board, Rights Group Says More>>

Peaceful Tree Planting Attacked By Zionist Settlers/soldiers

Peaceful tree planting attacked by zionist settlers and soldiers, two Palestinians hospitalised and a German activist arrested. More>>

Get More From Scoop

 
 
 
 
 
World
Search Scoop  
 
 
Powered by Vodafone
NZ independent news